LUBRICIN
Biological
Novartis Pharmaceuticals Corporation
Total Payments
$316,835
Transactions
61
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $316,835 | 61 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $316,835 | 61 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-MASKED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECF843 VS VEHICLE IN SUBJECTS WITH DRY EYE DISEASE | Novartis Pharmaceuticals Corporation | $316,835 | 0 |
Top Doctors Receiving Payments for LUBRICIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Las Vegas, NV | $316,835 | 61 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $316,835
Product Information
- Type Biological
- Total Payments $316,835
- Total Doctors 0
- Transactions 61
About LUBRICIN
LUBRICIN is a biological associated with $316,835 in payments to 0 healthcare providers, recorded across 61 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $316,835 was paid across 61 transactions to 0 doctors.
The most common payment nature for LUBRICIN is "Unspecified" ($316,835, 100.0% of total).
LUBRICIN is associated with 1 research study, including "A RANDOMIZED, DOUBLE-MASKED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECF843 VS VEHICLE IN SUBJECTS WITH DRY EYE DISEASE" ($316,835).